Does Liothyronine Sodium Interact with Cholestyramine Light?
CDI records a moderate classification for Liothyronine Sodium and Cholestyramine Light. The stored summary is: Bile acid sequestrant that may decrease T3 absorption by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Administer liothyronine sodium at least 4 hours prior. The mechanism involves binding and delayed/prevented absorption. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Cholestyramine Light Class
- Bile Acid Sequestrant
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Binding and delayed/prevented absorption
What To Tell Your Doctor or Pharmacist
If you are taking Liothyronine Sodium and your doctor is considering prescribing Cholestyramine Light (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider